【摘要】：目的觀察阿托伐他汀聯(lián)合尤瑞克林治療急性腦梗死患者的臨床療效及對(duì)內(nèi)皮素(ET)的影響,分析其療效影響因素。方法 180例急性腦梗死患者按隨機(jī)數(shù)字表分為觀察組90例和對(duì)照組90例,兩組給予常規(guī)治療,包括抗血小板、他汀類藥物、神經(jīng)保護(hù)劑、改善血液循環(huán)藥物,對(duì)照組他汀類藥物選擇阿托伐他汀,20 mg/次,qd,觀察組在對(duì)照組的基礎(chǔ)上再給予尤瑞克林治療,0.15 PNAU/次,qd,連續(xù)治療2 w,治療前后進(jìn)行腦卒中量表(NIHSS)評(píng)分及日常生活能力(ADL)評(píng)分,評(píng)價(jià)臨床療效,采用放射免疫分析法測(cè)定血漿ET含量,分析臨床療效的影響因素〔年齡、性別、吸煙、飲酒、高血壓、糖尿病、心臟病、高脂血癥、低分子肝素試驗(yàn)(TOAST)分型、牛津郡社區(qū)腦卒中項(xiàng)目(OCSP)分型〕。結(jié)果觀察組臨床總有效率明顯高于對(duì)照組(P0.05),觀察組和對(duì)照組治療后NIHSS評(píng)分、ET水平較治療前明顯降低(P均0.05),ADL評(píng)分較治療前明顯升高(P均0.05),觀察組治療后NIHSS評(píng)分、ET水平明顯低于對(duì)照組(P0.05),ADL評(píng)分明顯高于對(duì)照組(P0.05)。糖尿病及TOAST分型是影響阿托伐他汀聯(lián)合尤瑞克林療法的影響因素,糖尿病患者臨床療效降低,小動(dòng)脈閉塞型(SAO)患者效果更佳,年齡、性別、吸煙、飲酒、高血壓、心臟病、高脂血癥、OCSP分型對(duì)阿托伐他汀聯(lián)合尤瑞克林療法的療效無影響。結(jié)論阿托伐他汀聯(lián)合尤瑞克林治療急性腦梗死患者可有效改善神經(jīng)功能缺損,恢復(fù)ADL,效果明顯優(yōu)于常規(guī)療法,與其對(duì)抗血管收縮有關(guān),其效果受糖尿病及TOAST分型影響,臨床醫(yī)師應(yīng)考慮血糖控制及臨床分型,規(guī)范臨床治療。
[Abstract]:Objective to observe the clinical effect of Atto vastatin combined with eucrine in the treatment of acute cerebral infarction and its effect on endothelin (ET), and to analyze the influencing factors. Methods 180 patients with acute cerebral infarction were randomly divided into the observation group (n = 90) and the control group (n = 90). The two groups were given routine treatment, including antiplatelet, statins, neuroprotective agents, and improving blood circulation. In the control group, the statins were selected as Atto vastatin for 20 mg/, and the qd, observation group was treated with eucrine on the basis of the control group for 0. 15 PNAU/ and qd, for 2 weeks. Before and after treatment, stroke scale (NIHSS) score and ADL (ADL) score were used to evaluate clinical efficacy, plasma ET content was measured by radioimmunoassay, and the influencing factors (age, sex, smoking, alcohol consumption) were analyzed. Hypertension, diabetes, heart disease, hyperlipidemia, low molecular weight heparin test (TOAST) typing, Oxfordshire Community Stroke Project (OCSP) typing. Results the total clinical effective rate in the observation group was significantly higher than that in the control group (P0.05). The NIHSS score and ET level in the observation group and the control group were significantly lower than those before treatment (P 0.05). The NIHSS score and ET level in the observation group were significantly lower than those in the control group (P0.05), ADL score was significantly higher than that in the control group (P0.05). Diabetes mellitus and TOAST classification were the influencing factors of Atto vastatin combined with eucrine therapy. The clinical efficacy of patients with diabetes was lower than that of patients with arterio-occlusive (SAO). Age, sex, smoking, drinking, high blood pressure, heart disease, age, sex, smoking, drinking, hypertension, heart disease, Hyperlipidemia, OCSP typing had no effect on the efficacy of Atto vastatin combined with eurekline. Conclusion Atto vastatin combined with eurexacin can effectively improve the neurological function of patients with acute cerebral infarction, and the effect of ADL, recovery is better than that of routine therapy, which is related to the antivasoconstriction effect, and its effect is affected by diabetes mellitus and TOAST classification. The clinician should consider the blood sugar control and clinical classification, standardize the clinical treatment.
【作者單位】： 萊蕪市人民醫(yī)院保健二科;
【分類號(hào)】：R743.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 姚建華;宋春伶;楊鑫;;尤瑞克林治療基底動(dòng)脈尖綜合征30例臨床觀察[J];中國(guó)老年學(xué)雜志;2008年18期

2 林興建;過燕萍;徐俊;孫豐;陳俊;張穎冬;;尤瑞克林治療短暫性腦缺血發(fā)作的療效觀察[J];山東醫(yī)藥;2009年01期

3 方伯言;賈玉潔;楊波;楊銳;賈寧;閔連秋;;尤瑞克林治療短暫性腦缺血發(fā)作26例療效觀察[J];山東醫(yī)藥;2009年37期

4 陳玉s，

本文編號(hào)：2370290